Open AccessCisplatin-Induced Peripheral Neuropathy: An Observational Descriptive Study
Author(s) -
Anjol Kurian,
B Suresh Babu,
Benson Punnoose,
Chinju Susan Chacko,
Mallikarjuna Rao,
Sharad Chand,
B C Vinay,
U P Nandakumar
Publication year - 2020
Publication title -
international journal of research in pharmaceutical sciences
Language(s) - English
Resource type - Journals
ISSN - 0975-7538
DOI - 10.26452/ijrps.v11i3.2515
Subject(s) - peripheral neuropathy , medicine , common terminology criteria for adverse events , cisplatin , chemotherapy induced peripheral neuropathy , adverse effect , observational study , peripheral , cumulative dose , chemotherapy , surgery , diabetes mellitus , endocrinology
Peripheral neurotoxicity is a major adverse effect of cisplatin chemotherapy. A prospective observational study was conducted among 200 cancer patients who received cisplatin between October 2017 and March 2018 to evaluate the occurrence, causality and severity of cisplatin induced peripheral neuropathy. A suitable data collection form was used to record patient information required for the study. Peripheral neuropathy was assessed using the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE). As per the results, 19 (9.5%) patients developed peripheral neuropathy after receiving cisplatin therapy. Peripheral neuropathy was reported higher in males (84.2%) compared to females (15.7%) and more within the age group of 58-65 years (38.6%). Most of the patients developed Grade I neuropathy (84.2%), followed by Grade II neuropathy (15.7%). The study concluded that the severity of peripheral neuropathy increases with higher cumulative doses of cisplatin.